Showcasing Non-Cytotoxic Payload Attributes, Selection & Performance to Enhance ADC Therapeutic Index Beyond the Cytotoxic Dogma

• Understanding the importance of antibody epitope, influence of target isoforms and impact on internalization
• Unveiling detailed investigation of unique payloads to develop non-cytotoxic ADCs with improved therapeutic index beyond traditional conjugates
• Undergoing investigation of antigen internalization and tumor cell payload concentration to secure in-depth mechanistic understanding and benefit of antibody-mediated delivery
• Laying out takeaways for non-cytotoxic ADC development and applications to internal ADC development

Speakers:

Gail Lewis

Distinguished Scientist, Discovery Oncology

Genentech